Brief · 2026-07-01

Likang Life Sciences Launches AI Vaccine Plant

China is accelerating its personalized cancer vaccine infrastructure with Likang Life Sciences launching an AI-powered manufacturing facility, signaling a shift toward industrial-scale production.economy.ac

In clinical development, two distinct approaches for glioblastoma are advancing: GT Biopharma’s GNOS-PV01 DNA vaccine in Phase 1 and YSCell’s autologous dendritic cell therapy in an investigator-initiated dose-escalation trial.Oncodaily trial

4new stories

ClinicaltodayNew

Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma

Beijing YSCell Biotech is launching an investigator-initiated, open-label Phase 1 trial for YS247, a tumor neoantigen-pulsed autologous dendritic cell injection for recurrent or progressive glioblastoma. The study employs a '3+3' dose-escalation design across three cohorts to assess safety, tolerability, and preliminary efficacy. Patients will receive subcutaneous injections every two weeks for eight doses.

clinicaltrials · today · Huanhu Hospital Affiliated to Tianjin Medical University

Also new today03

CommercialtodayNew

Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Expansion into Early-Stage NSCLC - Slideshow (OTCMKTS:TRGNF) 2026-07-01 - Seeking Alpha

Transgene SA is expanding its pipeline of individualized neoantigen therapeutic vaccines into early-stage non-small cell lung cancer (NSCLC). The company’s recent updates highlight progress in developing personalized immunotherapies beyond their current indications, signaling an effort to diversify the application of their neoantigen platform across major oncology markets.

news · today · Seeking Alpha

Commercial3 days agoNew

"AI Reshapes Drug Development" China Targets Biotech Dominance with Government-Backed AI-Powered Personalized Cancer Vaccine Manufacturing Plant - economy.ac

Likang Life Sciences is constructing China’s first AI-powered manufacturing line for personalized tumor vaccines, with a $15.3 million investment aimed at scaling production to meet domestic demand. Scheduled to open in October, the facility integrates AI into the R&D and manufacturing workflow, reflecting a broader strategic push by Chinese biotech to leverage government support and regulatory innovation for commercial dominance.

news · 3 days ago · economy.ac

Clinicallast weekNew

GT-20 Trial: Personalized Neoantigen Vaccines for Glioblastoma - Oncodaily

GT Biopharma’s GNOS-PV01, a personalized DNA vaccine targeting patient-specific mutations in MGMT-unmethylated glioblastoma, is being evaluated in a Phase 1 study published in Nature Cancer. The trial utilizes multi-regional tumor sampling to address high heterogeneity, aiming to induce immune responses against dozens of neoantigens rather than single targets. This approach addresses the lack of efficacy seen with prior immunotherapies in this aggressive cancer subtype.

news · last week · Oncodaily